SANA Company Profile and Key Details

Q: Who are the executives of SANA?

Dr. Edward Rebar Ph.D.Senior Vice President & Chief Technology OfficerMs. Shanna Clouse PeekSenior Vice President & Head of Corporation OperationsDr. Sunil Agarwal M.D.Executive Vice President, Head of Devel. & Chief Medical OfficerMs. Donna Dambach D.V.M., Ph.D.Senior Vice President & Head of Devel. SciencesDr. Richard C. Mulligan Ph.D.Executive Vice Chairman & Head of SanaXDr. Steven D. Harr M.D.Pres, Chief Executive Officer & DirectorBrittany MccleeryAccounting Mang.Mr. Nathan Hardy M.B.A.Executive Vice President & Chief Financial OfficerDr. Sonja Schrepfer M.D., Ph.D.Senior Vice President & Head of Hypoimmune PlatformMr. Christian Hordo M.B.A.Executive Vice President & Chief Bus. OfficerMr. Bernard J. Cassidy J.D.Executive Vice President, Gen. Counsel & Corporation Sec.Mr. Paul Brunetta M.D.Senior Vice President and Head of Clinical & Translational ScienceMs. Robin AndrulevichExecutive Vice President & Chief People Officer

NASDAQ : SANA

Sana Biotechnology

$2.68

-0.09-3.25%

Open: 4:00 PM

63.97

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Sana Biotechnology, Inc. (SANA) stock declined over -3.25%, trading at $2.68 on NASDAQ, down from the previous close of $2.77. The stock opened at $2.77, fluctuating between $2.67 and $2.85 in the recent session.

Stock Snapshot

2.77

Prev. Close

745.82M

Market Cap

2.67

Day Low

-2.91

P/E Ratio

-0.92

EPS (TTM)

-1.39

Cash Flow per Share

2.77

Open

278.29M

Number of Shares

2.85

Day High

65.76%

Free Float in %

1.46

Book Value

2.23M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 12, 2026	2.77	2.85	2.67	2.68	2.25M
Jun 11, 2026	2.82	2.88	2.74	2.77	2.95M
Jun 10, 2026	2.76	2.91	2.76	2.82	2.68M
Jun 09, 2026	2.73	2.92	2.65	2.82	8.72M
Jun 08, 2026	2.74	2.75	2.61	2.69	3.34M
Jun 05, 2026	2.93	2.95	2.66	2.68	4.65M
Jun 04, 2026	3.13	3.25	2.94	2.96	4.19M
Jun 03, 2026	3.23	3.25	3.08	3.12	2.57M
Jun 01, 2026	3.29	3.38	3.14	3.21	3.4M
May 29, 2026	3.13	3.33	3.07	3.30	5.01M
May 28, 2026	3.04	3.20	2.98	3.13	6.17M
May 27, 2026	3.06	3.23	3.01	3.06	3.54M
May 26, 2026	3.08	3.17	2.97	3.05	4.04M
May 22, 2026	3.19	3.25	3.06	3.07	4.18M
May 21, 2026	3.05	3.18	3.01	3.15	2.06M
May 20, 2026	3.06	3.17	3.06	3.11	2.94M
May 19, 2026	2.97	3.15	2.91	3.06	3.39M
May 18, 2026	3.07	3.15	2.98	3.04	2.95M
May 15, 2026	3.05	3.11	2.96	3.07	3.7M
May 14, 2026	3.23	3.28	3.08	3.14	22.77M

Contact Details

Seattle, WA 98102

United States

https://www.sana.com 206 701 7914

About Company

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

Stock Peers

ARGX

-5.42-0.60%

argenx SE$893.52 REGN

0.66+0.11%

Regeneron Pharmaceuticals, Inc.$612.14 UTHR

0.56+0.10%

United Therapeutics Corporation$545.96 MDGL

6.49+1.37%

Madrigal Pharmaceuticals, Inc.$480.77 VRTX

-0.115-0.03%

Vertex Pharmaceuticals Incorporated$444.93 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

-3.575-1.11%

Krystal Biotech, Inc.$317.97 ALNY

-6.54-2.26%

Alnylam Pharmaceuticals, Inc.$282.85 PRAX

18.6+7.50%

Praxis Precision Medicines, Inc.$266.58 LGND

0.97+0.38%

Ligand Pharmaceuticals Incorporated$255.54

Company Overview

Sana Biotechnology, Inc. (NASDAQ:SANA) closed at $2.68 USD, losing -$0.09 (-3.25%) from the previous close of $2.77. The stock is currently mid-range between its 52-week high and low $2.43 and $6.55. With a market capitalization of about $745.82 million, Sana Biotechnology, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.16). Key stats such as the average daily volume over the past year has been around 3.75 million shares, volume is running light vs its 52-week average. Headquartered in Seattle, WA, Sana Biotechnology, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Steven D. Harr, the company employs approximately 194 people and listed since February 04, 2021. Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells.

Technical Performance

SANA has shown mixed momentum, losing 0.0% over the past week and -8.95% over the past quarter, though year-to-date performance is up 12.53%. Short-term trend indicators are mixed aligned (SMA20 4.62%, SMA50 -2.52%, SMA200 11.81%). The stock’s 14-day RSI is 52.13 (neutral), while the ATR of 0.29 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -34.81% below its high and over 238.89% above its low. Average 10-day trading volume of 3.92 million shares is in line with the 3-month average of 3.80 million, indicating normal recent market interest.

Valuation Metrics

Sana Biotechnology, Inc. trades at a P/E ratio of -3.12, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 6.33 trading at moderately above to book value. The P/FCF stands at -5.67, also above market averages.

Dividend & Fair Value

Sana Biotechnology, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.03. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Sana Biotechnology, Inc. generated EPS of -$0.97 over the past year. Five-year average earnings growth is -10.6%. Wall Street analysts project EPS growth of 19.3% annually over the next five years. The latest quarter delivered EPS of -$0.14. The next quarter is forecast at -$0.14. Next year's EPS is expected at $29.73. Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $5.00. The high target offers 347.76% upside. The low target suggests 86.57% downside. The mean target is $7.56. This offers 182.09% upside. Sana Biotechnology, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 11, 2026, missed forecasts by -6.67%. The prior quarter beat by 23.08%. Over the last six quarters, Apple has recorded several small beats. These include -8.0% in March 17, 2025.

Shareholding & Insider Activity

Sana Biotechnology, Inc. has 253.89 million shares outstanding. The public float is 155.38 million shares, elevated short interest at 39.14% of float. This equals 33.35 million shares. The short ratio is 5.55 days. Institutional investors hold 80.75% of the float. Insiders own 6.83%. CRANDELL KEITH holds 10.67 million shares, NELSEN ROBERT has 10.67 million shares and ARCH Venture Fund X, L.P. has 10.67 million shares.

Financial & Profitability Overview

Over the trailing twelve months, Sana Biotechnology has not generated any revenue. Returns are negative, with ROA at -50.11% and ROE at -98.52%.
On valuation metrics, Sana Biotechnology trades at a P/E of -3.12, P/S of 0.00 and P/B of 6.33. The current ratio is 1.29 and quick ratio is 1.29. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -324.09 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.63, supported by a cash flow-to-debt ratio of -1.76.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Sana Biotechnology posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $30.87M (margin 0.00%). Operating income was - $325.81M (margin 0.0%). Net income was- $283.26M (EPS - $1.46).
The company ended the quarter with $209.03M in cash and short-term investments, a total debt of $104.10M, and net debt of - $33.25M. Total assets were $565.30M, with equity of $287.51M. Financials further reflected weakness, with operating cash flow of - $253.58M, free cash flow of - $273.61M, and capital expenditures of - $20.03M.

Price Forecast & Outlook

Our AI price prediction model suggests that Sana Biotechnology, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.34%, with price expected at $2.51 by June 26, 2026, within a range of $2.32 to $2.70 3-Month Outlook: Projected fall of -76.87%, reaching $0.62 by September 10, 2026, with a range of $0.43 to $0.77. 1-Year Outlook: Projected loss of -14.18%, with price at $2.30 by June 11, 2027, within a range of $0.00 to $0.02.

Key Takeaways

Sana Biotechnology, Inc. (NASDAQ:SANA) shares are up 12.53% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Sana Biotechnology, Inc. trading at a premium to the broader market with a P/E of -3.12. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $10.05, suggesting 275.0% upside. Our AI forecast model points to short-term weakness (-6.34% over two weeks), a medium-term fall (-76.87% over three months), and a longer-term loss (-14.18% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Sana Biotechnology, Inc. (SANA) stock price?

Sana Biotechnology, Inc. (NASDAQ: SANA) stock price is $2.68 in the last trading session. During the trading session, SANA stock reached the peak price of $2.85 while $2.67 was the lowest point it dropped to. The percentage change in SANA stock occurred in the recent session was -3.25% while the dollar amount for the price change in SANA stock was - $0.09.

SANA's industry and sector of operation?

The NASDAQ listed SANA is part of Biotechnology industry that operates in the broader Healthcare sector. Sana Biotechnology, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of SANA?

Dr. Edward Rebar Ph.D.
Senior Vice President & Chief Technology Officer
Ms. Shanna Clouse Peek
Senior Vice President & Head of Corporation Operations
Dr. Sunil Agarwal M.D.
Executive Vice President, Head of Devel. & Chief Medical Officer
Ms. Donna Dambach D.V.M., Ph.D.
Senior Vice President & Head of Devel. Sciences
Dr. Richard C. Mulligan Ph.D.
Executive Vice Chairman & Head of SanaX
Dr. Steven D. Harr M.D.
Pres, Chief Executive Officer & Director
Brittany Mccleery
Accounting Mang.
Mr. Nathan Hardy M.B.A.
Executive Vice President & Chief Financial Officer
Dr. Sonja Schrepfer M.D., Ph.D.
Senior Vice President & Head of Hypoimmune Platform
Mr. Christian Hordo M.B.A.
Executive Vice President & Chief Bus. Officer
Mr. Bernard J. Cassidy J.D.
Executive Vice President, Gen. Counsel & Corporation Sec.
Mr. Paul Brunetta M.D.
Senior Vice President and Head of Clinical & Translational Science
Ms. Robin Andrulevich
Executive Vice President & Chief People Officer

How SANA did perform over past 52-week?

SANA's closing price is 11.2% higher than its 52-week low of $2.43 where as its distance from 52-week high of $6.55 is -59.08%.

How many employees does SANA have?

Number of SANA employees currently stands at 194.

Link for SANA official website?

Official Website of SANA is: https://www.sana.com

How do I contact SANA?

SANA could be contacted at phone 206 701 7914 and can also be accessed through its website. SANA operates from 188 East Blaine Street, Seattle, WA 98102, United States.

How many shares of SANA are traded daily?

SANA stock volume for the day was 2.23M shares. The average number of SANA shares traded daily for last 3 months was 3.75M.

What is the market cap of SANA currently?

The market value of SANA currently stands at $745.82M with its latest stock price at $2.68 and 278.29M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	194
Beta	1.96
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

SANA Company Profile and Key Details

Sana Biotechnology

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Earnings & Analyst Outlook

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways